A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Active, not recruiting · NCT03912064 · Registry updated 2026-01-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute myeloid leukemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, primary myelofibrosis | Active, not recruiting | Phase 1 | 2026-01-05 | NCT03912064 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| National Cancer Institute (NCI) | 3015 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 511 |
| Dana Farber Cancer Institute | Boston | United States | 133 |